The latest weapon in the battle against cancer is showing promising results — and it's a growing opportunity for investors, according to Redburn Atlantic.
To treat cancer, targeted radiopharmaceutical therapy directly goes after tumors with radiation by binding a radioactive particle to a targeting molecule.
Delving into diagnostics There are also opportunities in the radiopharma diagnostics space, according to Redburn Atlantic.
It has a "strong pipeline of radionuclides for both diagnosis and therapy," he said.
"Lantheus benefits from its focus on this rapidly expanding market, with 78% of revenues from radiopharmaceuticals and related products," Ridley-Day added.
Persons:
Ed Ridley, Eli Lilly, Myers, Ridley, Astra's, Lantheus
Organizations:
Big pharma, Novartis, Mariana Oncology, Biopharma, Myers Squibb, RayzeBio, AstraZeneca, Fusion Pharmaceuticals, GE Healthcare Technologies, Lantheus Holdings, GE Healthcare, GE
Locations:
Bristol, radiopharmaceuticals